CpG 7909, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Treatment - Contacts and Locations

CpG 7909, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Treatment

This study is ongoing, but not recruiting participants.

Study NCT00438880. Last updated on July 23, 2008. Information provided by National Cancer Institute (NCI)

Please refer to this study by its ClinicalTrials.gov identifier: NCT00438880

Locations


United States, Iowa
	Holden Comprehensive Cancer Center at University of Iowa
	Iowa City, Iowa, United States, 52242-1002

United States, Minnesota
	Mayo Clinic Cancer Center
	Rochester, Minnesota, United States, 55905

Sponsors and Collaborators

Mayo Clinic

National Cancer Institute (NCI)

Investigators


Study Chair:	Thomas E. Witzig, MD	Mayo Clinic

Investigator:	Gregory Wiseman, MD	Mayo Clinic

Investigator:	George J. Weiner, MD	Holden Comprehensive Cancer Center

Investigator:	Stephen M. Ansell, MD, PhD	Mayo Clinic

Investigator:	Joseph P. Colgan, MD	Mayo Clinic

Investigator:	Thomas M. Habermann, MD	Mayo Clinic

Investigator:	David J. Inwards, MD	Mayo Clinic

Investigator:	Patrick Johnston, MD, PhD	Mayo Clinic

Investigator:	Paul Kurtin, MD	Mayo Clinic

Investigator:	Svetomir Markovic, MD, PhD	Mayo Clinic

Investigator:	Luis F. Porrata, MD	Mayo Clinic

Investigator:	William L. White, MD	Mayo Clinic

Investigator:	Ivana Micallef, MD	Mayo Clinic